Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Intangibles (2016 - 2025)

Historic Intangibles for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $3.8 billion.

  • Teva Pharmaceutical Industries' Intangibles fell 1441.83% to $3.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.8 billion, marking a year-over-year decrease of 1441.83%. This contributed to the annual value of $3.8 billion for FY2025, which is 1441.83% down from last year.
  • Teva Pharmaceutical Industries' Intangibles amounted to $3.8 billion in Q4 2025, which was down 1441.83% from $3.9 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Intangibles high stood at $8.4 billion for Q1 2021, and its period low was $3.8 billion during Q4 2025.
  • In the last 5 years, Teva Pharmaceutical Industries' Intangibles had a median value of $5.6 billion in 2023 and averaged $5.8 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Intangibles tumbled by 1837.33% in 2022 and then crashed by 1357.74% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Intangibles stood at $7.5 billion in 2021, then decreased by 16.02% to $6.3 billion in 2022, then decreased by 14.08% to $5.4 billion in 2023, then decreased by 17.99% to $4.4 billion in 2024, then fell by 14.42% to $3.8 billion in 2025.
  • Its last three reported values are $3.8 billion in Q4 2025, $3.9 billion for Q3 2025, and $4.1 billion during Q2 2025.